Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKN1 | Q16512 | 1/20 | 0.53 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.53 |
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.52 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.52 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20306812 | 0.89 | ALDH1A1 (0.49) | PKN1PKN2SIRT2SIRT1SIRT3 | |
| SCHEMBL1370518 | 0.88 | HCRTR1 (0.52) | PKN1PKN2SIRT2SIRT1SIRT3 | |
| SCHEMBL20306811 | 0.85 | PKN1 (0.39) | PKN1PKN2SIRT2SIRT1SIRT3 | |
| SCHEMBL18671246 | 0.84 | SIRT2 (0.41) | PKN1PKN2SIRT2SIRT1SIRT3 | |
| SCHEMBL18671256 | 0.84 | PKN1 (0.40) | PKN1PKN2SIRT2SIRT1SIRT3 | |
| SCHEMBL17106463 | 0.83 | ALDH1A1 (0.44) | PKN1PKN2SIRT2SIRT1SIRT3 | |
| SCHEMBL9871375 | 0.83 | KDM4E (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL20306813 | 0.83 | LMNA (0.41) | PKN1PKN2SIRT2SIRT1SIRT3 | |
| SCHEMBL18671245 | 0.83 | PKN1 (0.39) | PKN1PKN2SIRT2SIRT1SIRT3 | |
| SCHEMBL17548962 | 0.81 | PKN1 (0.38) | PKN1PKN2SIRT2SIRT1SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220162192-A1 | INDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2022-05-26 | — | — | US | disclosed |
| WO-2020191261-A1 | INDAZOLES AS LRRK2 INHIBITORS | E-SCAPE BIO, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| US-9929348-B2 | Organic semiconductor composition comprising organic semiconductor material and polymer compound | FUJIFILM CORPORATION (JP) | 2018-03-27 | — | — | US | disclosed |
| US-20160064674-A1 | ORGANIC SEMICONDUCTOR COMOSITION, ORGANIC THIN-FILM TRANSISTOR, ELECTRONIC PAPER, AND DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2016-03-03 | — | — | US | disclosed |
| US-9238647-B2 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2016-01-19 | — | — | US | disclosed |
| EP-2410857-B1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME (US) | 2014-01-29 | — | — | EP | disclosed |
| US-20120064181-A1 | P2X3 Receptor Antagonists for Treatment of Pain | MERCK SHARP & DOHME LLC | 2012-03-15 | — | — | US | disclosed |
| EP-2410857-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | Merck Sharp & Dohme Corp. (US) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010111058-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME CORP. (US) | 2010-09-30 | — | — | WO | disclosed |
| CN-1735592-A | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | GLAXO GROUP LTD (GB) | 2006-02-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064181-A1 | P2X3 Receptor Antagonists for Treatment of Pain | P2RX3, P2RX1, P2RX2 | PKN1 2814/4885PKN2 3628/4885SIRT2 4562/4885 |
| US-20220162192-A1 | INDAZOLES AS LRRK2 INHIBITORS | LRRK2, PARK7, PINK1 | PKN1 1177/4885PKN2 485/4885SIRT2 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.